Physician profile
Randy A Lieberman
NPI 1679513543
$1,184,124.36
in general payments reported to CMS, 2019-2025
33 companies · $33K in 2025
The $33K reported for 2025 was more than what 93% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173K · 2020: $219K · 2021: $244K · 2022: $273K · 2023: $158K · 2024: $84K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $234K · Travel and Lodging: $13K · Food and Beverage: $9,526 · Consulting Fee: $9,486 · Honoraria: $9,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $234,104.69 |
| Travel and Lodging | $12,943.35 |
| Food and Beverage | $9,525.98 |
| Consulting Fee | $9,486.00 |
| Honoraria | $9,190.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $384,335.59 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $373,944.29 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100,233.35 | 2020-2024 | Jardiance |
| Amgen INC. | $80,034.12 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $51,881.67 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $49,829.84 | 2021-2024 | Verquvo |
| Pfizer INC. | $45,730.77 | 2019-2025 | |
| Lilly USA, LLC | $29,022.24 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $25,075.15 | 2024-2025 | Wegovy |
| Elutia, INC. | $15,193.68 | 2019-2023 | |
| Medtronic, INC. | $14,134.89 | 2021-2025 | Linq II, Micra, Cobalt Dr Mri Surescan |
| Itamar Medical INC | $3,817.79 | 2023-2024 | Watchpatone |
| Medtronic Vascular, INC. | $2,982.71 | 2019-2020 | |
| Abbott Laboratories | $2,071.07 | 2022-2025 | Aveir, Cardiomems |
| Impulse Dynamics (USA) INC. | $1,503.77 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $1,125.00 | 2024 | Sotalol Hydrochloride |
| Kestra Medical Technology Services, INC. | $611.15 | 2024-2025 | Assure Wcd |
| Boston Scientific Corporation | $605.12 | 2023-2025 | Emblem Mri S-Icd, Empower Leadless Pacemaker System_crm, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $574.98 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $514.71 | 2019-2025 | Eliquis |
| Alnylam Pharmaceuticals INC. | $286.43 | 2024-2025 | Amvuttra |
| Zoll Respicardia, INC. | $148.82 | 2019 | |
| Medtronic USA, INC. | $136.60 | 2019 | |
| Cordis US Corp. | $79.74 | 2025 | Mynx Control Venous, Mynxgrip |
| Novartis Pharmaceuticals Corporation | $77.20 | 2020-2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $37.06 | 2022 | |
| Sobi, INC | $36.76 | 2021 | |
| Edwards Lifesciences Corporation | $34.24 | 2024 | Pascal |
| Cleerly, INC. | $34.10 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Dynavax Technologies Corporation | $14.80 | 2022 | |
| Cardiofocus, INC. | $12.50 | 2022 | |
| Janssen Scientific Affairs, LLC | $4.22 | 2024 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.